Psoriasis is a chronic autoimmune skin disorder that affects millions of people worldwide, causing red, scaly patches, inflammation, and significant impacts on quality of life. With growing awareness of advanced therapies and continuous pharmaceutical innovation, demand for biologics for psoriasis, effective plaque psoriasis treatment, and next-generation psoriasis biologic drugs continues to rise. These developments are driving strong expansion in the Psoriasis Drug Market, as healthcare providers increasingly adopt targeted therapies that offer superior clinical outcomes compared to conventional treatments.

The global Psoriasis Drug Market was valued at USD 20.52 billion in 2024 and is expected to reach USD 22.63 billion in 2025. The market is projected to grow at a CAGR of 10.8% from 2025 to 2034, reaching approximately USD 56.96 billion by 2034.

Rising Demand for Advanced Plaque Psoriasis Treatment

Plaque psoriasis is the most common form of psoriasis, accounting for the majority of diagnosed cases worldwide. The condition results from an overactive immune system that accelerates skin cell production, leading to persistent plaques, itching, and discomfort. Although topical therapies remain suitable for mild disease, moderate-to-severe cases often require systemic therapies and biologic medications.

Modern plaque psoriasis treatment focuses on reducing inflammation, preventing disease progression, minimizing flare-ups, and improving patients' long-term quality of life. Healthcare providers increasingly favor personalized treatment strategies based on disease severity, patient characteristics, and immune biomarkers.

The growing emphasis on early diagnosis and long-term disease management continues to strengthen the Psoriasis Drug Market, encouraging pharmaceutical companies to develop highly targeted therapies with improved efficacy and safety profiles.

Biologics for Psoriasis Revolutionize Patient Care

The introduction of biologics for psoriasis has significantly transformed the management of moderate-to-severe disease. Unlike traditional systemic medications that broadly suppress immune activity, biologics target specific inflammatory pathways responsible for psoriasis development.

Many biologic therapies inhibit cytokines such as tumor necrosis factor (TNF), interleukin-17 (IL-17), interleukin-23 (IL-23), and interleukin-12/23, offering highly targeted immune modulation with improved clinical outcomes.

These therapies have demonstrated remarkable success in reducing skin lesions, lowering relapse rates, and improving patients' overall quality of life. The expanding use of biologics, together with ongoing research into biosimilars and next-generation immune-targeted therapies, continues to accelerate growth within the Psoriasis Drug Market.

Segment Analysis

By Therapeutic Class

The Psoriasis Drug Market is segmented into:

• Tumor Necrosis Factor (TNF) Inhibitors
• Interleukin Inhibitors
• Vitamin D Analogues
• Corticosteroids
• Others

Among these, Interleukin Inhibitors account for the largest market share due to their high efficacy in treating moderate-to-severe psoriasis and favorable safety profile. Continuous innovation in IL-17 and IL-23 inhibitors has further strengthened this segment, making it one of the fastest-growing categories within the market.

By Treatment

Based on treatment type, the market is categorized into:

• Topicals
• Systemic
• Biologics

The Biologics segment holds the largest revenue share and is expected to remain the fastest-growing treatment category throughout the forecast period. Increasing physician preference for targeted immune therapies and expanding regulatory approvals for innovative biologics continue to drive this segment's growth.

By Route of Administration

The market is further segmented into:

• Oral
• Parenteral
• Topical

The parenteral segment dominates the market due to the widespread use of injectable psoriasis biologic drugs. However, oral therapies are gaining momentum as pharmaceutical companies develop convenient treatment alternatives that improve patient adherence while maintaining high therapeutic efficacy.

Discover the Complete Report Here:

https://www.polarismarketresearch.com/industry-analysis/global-psoriasis-drug-market

List of Key Companies 

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca
• Boehringer Ingelheim International GmbH
• Celgene Corporation (a subsidiary of Bristol-Myers Squibb)
• Eli Lilly and Company
• Johnson & Johnson Services, Inc.
• LEO Pharma A/S
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• UCB S.A.

Regional Analysis

North America

North America leads the Psoriasis Drug Market, supported by advanced healthcare infrastructure, favorable reimbursement policies, high awareness levels, and rapid adoption of biologic therapies. Strong research and development activities, along with the presence of major pharmaceutical companies, continue to drive innovation in psoriasis treatment.

Europe

Europe represents a significant share of the global market due to increasing access to advanced biologic therapies, robust healthcare systems, and growing investments in autoimmune disease research. Countries such as Germany, France, Italy, and the United Kingdom continue to adopt innovative treatment approaches for psoriasis management.

Asia-Pacific

Asia-Pacific is projected to witness the fastest growth during the forecast period. Rising healthcare expenditure, improving diagnostic capabilities, increasing awareness of autoimmune diseases, and expanding access to biologic therapies are fueling market expansion across China, India, Japan, and South Korea. The growing patient population also presents substantial opportunities for pharmaceutical manufacturers.

Latin America and Middle East & Africa

These emerging regions are gradually expanding due to improved healthcare infrastructure, wider access to specialty dermatology services, and increasing awareness regarding advanced psoriasis treatment options. Government healthcare initiatives and the availability of biosimilars are expected to further support market growth.

Future Outlook

The future of the Psoriasis Drug Market remains highly promising as pharmaceutical companies continue investing in innovative biologics for psoriasis, biosimilars, and precision medicine approaches. Ongoing research into immune-targeted therapies, advanced drug delivery systems, and personalized treatment strategies is expected to further improve patient outcomes while expanding therapeutic options.

As demand for effective plaque psoriasis treatment continues to rise, the development of next-generation psoriasis biologic drugs will remain a major growth driver, positioning the global psoriasis therapeutics industry for sustained expansion over the next decade.

More Trending Latest Reports By Polaris Market Research:

Drug Delivery Market

Sinus Dilation Devices Market

North America Veterinary Clinical Trials Market

NAMPT Inhibitor Market

Blockchain In Healthcare Market

Private Nursing Services Market

Liposomal Doxorubicin Market

U.S. Liquid Embolic Agent Market